We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+1.01%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.07B
AUM Growth
+$158M
Cap. Flow
+$174M
Cap. Flow %
16.28%
Top 10 Hldgs %
64.66%
Holding
34
New
5
Increased
13
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
CDXS icon
Codexis
CDXS
+$58.8M
2
NVTA
Invitae Corporation
NVTA
+$34.9M
3
ADPT icon
Adaptive Biotechnologies
ADPT
+$20.5M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$15.7M
5
QTTB icon
Q32 Bio
QTTB
+$8.62M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$9.24M
2
EVH icon
Evolent Health
EVH
+$6.92M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$5.96M
4
GILD icon
Gilead Sciences
GILD
+$5.2M
5
BOLD
Audentes Therapeutics, Inc
BOLD
+$1.73M

Sector Composition

Rank Sector Weight
1 Healthcare 81.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TWST icon
26
Twist Bioscience
TWST
$6.29B
$8.7M 0.81%
+300,000
New +$7.94M
DNLI icon
27
Denali Therapeutics
DNLI
$3.67B
$8.3M 0.78%
400,000
+300,000
+300% +$6.72M
CDNA icon
28
CareDx
CDNA
$2.48B
$7.2M 0.67%
200,000
– –
STOK icon
29
Stoke Therapeutics
STOK
$1.84B
$2.48M 0.23%
+85,000
New +$2.28M
TPTX
30
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$2.44M 0.23%
+60,000
New +$2.14M
ORTX
31
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.4M 0.13%
+10,000
New +$1.76M
EVH icon
32
Evolent Health
EVH
$353M
– –
-550,000
Closed -$6.92M
GILD icon
33
Gilead Sciences
GILD
$163B
– –
-80,000
Closed -$5.2M
ONC
34
BeOne Medicines Ltd
ONC
$32.6B
– –
-70,000
Closed -$9.24M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q2 2019 Portfolio in Review

As of Q2 2019, Casdin Capital held 34 positions worth $1.07B, up 17% from $910M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Casdin Capital deployed $174M of net new capital in Q2 2019, opening 5 new positions and adding to 13 existing holdings. Its largest new stake was Adaptive Biotechnologies: 463,125 shares worth $20.1M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 80% a quarter earlier.

On the sell side, the largest reduction was Spark Therapeutics, Inc. Common Stock, an estimated $5.96M trimmed.

  • Casdin Capital's largest Q2 2019 buy was Adaptive Biotechnologies: 463,125 shares worth $20.1M.
  • Casdin Capital added most to Codexis in Q2 2019, an estimated $58.8M increase.
  • Casdin Capital's biggest Q2 2019 reduction was Spark Therapeutics, Inc. Common Stock, cutting an estimated $5.96M.
  • Casdin Capital fully exited BeOne Medicines Ltd in Q2 2019, selling an estimated $9.24M.
  • Casdin Capital's ten largest holdings make up 65% of its $1.07B portfolio in Q2 2019.
  • Casdin Capital opened 5 new positions and closed 3 in Q2 2019.
  • Casdin Capital's portfolio value rose 17% quarter-over-quarter to $1.07B.

Based on Casdin Capital's 13F filing for Q2 2019, filed 13 Aug 2019.